TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03671330

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribociclib Placebo
Description: Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribociclib
Description: Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAI: Letrozole or Anastrazole
Description: Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).~Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.~For postmenopausal and PK cohorts, all patients will be on Letrozole.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NSAI: Letrozole or Anastrazole
Description: Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).~Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.~For postmenopausal and PK cohorts, all patients will be on Letrozole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Goserelin
Description: Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle
Study: NCT04488536

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Frailty Scale
Description: Frailty assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Frailty Scale
Description: Frailty assessment
Study: NCT03389802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APX005M treatment for recurrent or refractory primary malignant CNS tumor patients
Description: APX005M dosing will begin at 0.1 mg/kg, the APX005M dose may be increased (0.3, 0.45, 0.6 mg/kg) or decreased (0.03 mg/kg) in subsequent cohorts until the maximum tolerated dose (MTD) is reached or until dose level 3 (0.6 mg/kg) is complete without the MTD being defined.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APX005M treatment for newly diagnosed DIPG patients
Description: The starting dose of APX005M for the DIPG patients will be one dose level below the recommended phase II dose (RP2D) determined in Stratum 1 patients. The dose may be decreased or increased to the RP2D established in Stratum 1.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first.
Study: NCT03052179

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Poly-biotic
Description: Before-after treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Poly-biotic
Description: Before-after treatment
Study: NCT03662945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Geriatric Team intervention
Description: Person-centred intervention based on Comprehensive Geriatric Assessment
Study: NCT01383538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX, IPI-926
Description: Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.~Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.~Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.~5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.~IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle.
Study: NCT00733317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg/ml budesonide nebules
Description: Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Children will receive 2 ml of saline every 20 minutes for 3 times
Study: NCT02759159

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: true acupuncture
Description: acupuncture at the four-gateacupoints, three times per week and last for 6 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: true acupuncture
Description: acupuncture at the four-gateacupoints, three times per week and last for 6 months

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: acupuncture at the places 1cm from the true four-gate acupoints,three times per week and last for 6 months

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: acupuncture at the places 1cm from the true four-gate acupoints,three times per week and last for 6 months
Study: NCT03609827

Intervention type: DRUG
Intervention: Melphalan
Study: NCT02692300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG-Guided Group
Description: Device: Bispectral Index (BIS) processed electroencephalogram or MASIMO or NeuroSENSE
Study: NCT02495753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal Cleansing
Description: The vagina will be prepped in two passes with sponge sticks soaked in 1% povidone-iodine solution from a prepackaged sterile pouch.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Cleansing
Description: The abdomen will be cleansed using chlorhexidine or betadine according to surgeon's preference prior to cesarean.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Cleansing
Description: The abdomen will be cleansed using chlorhexidine or betadine according to surgeon's preference prior to cesarean.
Study: NCT01710072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Study: NCT06470529

Intervention type: DEVICE
Intervention: drug eluting stents
Description: different types of drug eluting stents
Study: NCT04100772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）
Description: 0.5mL,Intramuscular other name:PCV13i

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）
Description: 0.5mL,Intramuscular other name:PCV13i

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）
Description: 0.5mL,Intramuscular other name:PCV13i

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）
Description: 0.5mL,Intramuscular other name:PCV13i

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）
Description: 0.5mL,Intramuscular other name:PCV13i

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）
Description: 0.5mL,Intramuscular other name:PCV13i

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）
Description: 0.5mL,Intramuscular other name:PCV13i

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: 0.5mL,Intramuscular other name:Prevnar
Study: NCT03355079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmofKabiven® E
Description: In the intervention arm, SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit®, will be administered in addition to standard of care oral nutrition as per dietary counseling, whereas in the control arm, oral nutrition as per dietary counseling is the primary nutritional support.
Study: NCT01494051

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet counseling
Description: Subjects counseled how to follow either the high carbohydrate diet or the high protein diet for 4 months at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet counseling
Description: Subjects counseled how to follow either the high carbohydrate diet or the high protein diet for 4 months at home.
Study: NCT01689116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl 20mg
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl 80mg
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl Placebo
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bardoxolone Methyl Placebo
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bardoxolone Methyl Placebo
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: Oral
Study: NCT02623673

Intervention type: DRUG
Intervention: simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.
Study: NCT01664078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular AAA repair with InCraft®
Study: NCT03743038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX101 vehicle
Description: FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydro-alcohol solution
Description: Hydro-alcohol solution based vehicle (Test Article B)
Study: NCT04215029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive exercise plan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive printed exercise materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive physical activity and healthy eating information/materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Complete nutrition counseling sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive coaching calls
Study: NCT02302079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8232
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8232
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: intravitreal (IVT) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: intravitreal (IVT) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: oral capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham intravitreal (IVT) injection
Description: intravitreal (IVT) injection
Study: NCT03286023

Intervention type: RADIATION
Intervention: stereotactic radiotherapy
Description: stereotactic radiotherapy for brain metastases
Study: NCT02500225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: 0.2 mg/kg etomidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: 0.2 mg/kg etomidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 8% Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 8% Sevoflurane
Study: NCT02167022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical and occupational therapy
Description: The type of physiotherapy to be administered is Perception-Action (P-A). The P-A (motor) intervention is a child-driven approach without the need for special equipment and considers the child and environment as a single unit.Treatment is a coupling of the child with the environment. The environment is changed to enable, enhance or stimulate movement. The action is initiated by the child with the therapist augmenting the child's environment using touch (tactile information) or light support (cushions, bolsters, and gentle touch or pressure) to assist and/or alter the child's active movement. Toys are used and positioned in different places to encourage movement of upper and lower extremities and the trunk; reaching, turning, sitting balance, crawling, walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical and occupational therapy
Description: The type of physiotherapy to be administered is Perception-Action (P-A). The P-A (motor) intervention is a child-driven approach without the need for special equipment and considers the child and environment as a single unit.Treatment is a coupling of the child with the environment. The environment is changed to enable, enhance or stimulate movement. The action is initiated by the child with the therapist augmenting the child's environment using touch (tactile information) or light support (cushions, bolsters, and gentle touch or pressure) to assist and/or alter the child's active movement. Toys are used and positioned in different places to encourage movement of upper and lower extremities and the trunk; reaching, turning, sitting balance, crawling, walking.
Study: NCT01517698

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to RO4917523 orally once a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523 0.5 mg
Description: 0.5 mg orally once a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523 1.5 mg
Description: 1.5 mg orally once a day for 12 weeks
Study: NCT03956498

Intervention type: OTHER
Group type: OTHER
Intervention: Patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy
Description: * Nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy.~* Questionnaires to be completed by the patient before brachytherapy, 2 months after the end of brachytherapy and 1 year after the end of brachytherapy : Female Sexual Function Index (FSFI), Quality of Life Questionnaire-Core 30 (QLQ-C30), and Quality-of-Life questionnaire cervical cancer module QLQ-CX24.
Study: NCT03822923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Neurodynamics with conventional treatment. Intervention will be applied for 6 weeks (10 reps per set, 1 set per day, 3 days per week) for 30 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Conventional treatment
Study: NCT03376321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimodivir 600 mg
Description: Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC Treatment
Description: Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SOC Treatment
Description: Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
Study: NCT03277313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
Study: NCT01700608

Intervention type: DRUG
Intervention: plerixafor
Description: plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy
Study: NCT02030977

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03340051

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Episodic Future Thinking (EFT)
Description: EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Episodic Recent Thinking (ERT)
Description: ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
Study: NCT01704092

Intervention type: DRUG
Intervention: Dexmedetomidine

Intervention type: DRUG
Intervention: Dexmedetomidine

Intervention type: DRUG
Intervention: Dexmedetomidine
Study: NCT01965834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance \< 50 mL/min will receive a reduced dose of 54 mg orally daily.
Study: NCT02863640

Intervention type: DEVICE
Intervention: Color retinography

Intervention type: DEVICE
Intervention: Color retinography

Intervention type: DEVICE
Intervention: Optical coherence tomography

Intervention type: DEVICE
Intervention: Optical coherence tomography

Intervention type: DEVICE
Intervention: Fundus autofluorescence imaging

Intervention type: DEVICE
Intervention: Fundus autofluorescence imaging
Study: NCT02342067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Description: CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
Study: NCT00423124

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HSV-TK
Description: Infusion of genetically modified lymphocytes (1x10\^6-1x10\^7 c/kg): first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
Study: NCT02276300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Treatment of mild Endoxan application three days before Her2 vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Sargramostim is part of Her2 vaccination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER2-Peptid-Vakzine
Description: Her2 vaccination is supplemented by Sargramostim and Aldara Creme application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod is part of Her2 vaccination
Study: NCT03068403

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration
Description: Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration
Description: Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration
Study: NCT03674177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3888550A RSV Maternal vaccine formulation 1
Description: Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3888550A RSV Maternal vaccine formulation 2
Description: Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3888550A RSV Maternal vaccine formulation 3
Description: Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal Saline)
Description: Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm